<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01132222</url>
  </required_header>
  <id_info>
    <org_study_id>431-04</org_study_id>
    <nct_id>NCT01132222</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets Under Fed Conditions</brief_title>
  <official_title>A Randomized, Open Label, 2-treatment, Single Dose, Crossover, Bioequivalence Study of Ibuprofen 200 mg+Pseudoephedrine HCL 30 mg Tablets of Dr. Reddy's and Advil® Cold and Sinus Caplets of Wyeth Consumer Healthcare Under Fed Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the bioequivalence of Ibuprofen 200 mg +
      Pseudoephedrine HCL 30 mg under fed conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study assess the bioequivalence of Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets
      of Dr. Reddy's and Advil® Cold and Sinus Caplets of Wyeth Consumer Healthcare in healthy
      human adult subjects with the single oral administration under fed conditions with a washout
      period of 7 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">October 2004</completion_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax and AUC parameters</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Ibuprofen + Psuedoephedrine Hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Advil® Cold and Sinus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Advil® Cold and Sinus Tablets of Wyeth Consumer Healthcare</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen + Pseudoephedrine Hydrochloride</intervention_name>
    <description>Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets</description>
    <arm_group_label>Ibuprofen + Psuedoephedrine Hydrochloride</arm_group_label>
    <arm_group_label>Advil® Cold and Sinus</arm_group_label>
    <other_name>Advil® Cold and Sinus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy human subjects between 18-50 years of age (inclusive), weighing as per the
             standard height and weight chart of Life Insurance Corporation of India (II
             Underweight and Overweight Min. &amp; Max. Chart)

          -  Subjects who have no evidence of underlying disease during screening medical history
             and whose physical examination is performed within 21 days to commencement of the
             study.

          -  Subjects whose screening laboratory values are within normal limits or considered by
             the physician/Principal Investigator to be of no clinical significance.

          -  Informed consent given in written form according to section 10.3 of the protocol.

          -  Female Subjects:

               1. of child bearing potential practicing an acceptable method of birth control for
                  the duration of study as judged by the investigator(s), such as condoms, foams,
                  jellies, diaphragm, intrauterine device (IUD), or abstinence.

               2. postmenopausal for at least 1 year.

               3. surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or
                  hysterectomy has been performed on the subject.

        Exclusion Criteria:

          1. History or presence of significant:

             i. Cardiovascular, pulmonary, hepatic, renal hematological; gastrointestinal,
             endocrine, immunologic, dermatologic, musculoskeletal, neurological or psychiatric
             disease.

               -  Alcohol dependence, alcohol abuse or drug abuse within past one year.

               -  Moderate to heavy smoking (&gt; 10 cigarettes/day) or on assumption of tobacco
                  products.

               -  History of difficulty in swallowing.

               -  Clinically significant illness within 4 weeks before the start of the study

               -  Asthma, urticaria or other allergic type reactions after taking any medication.

          2. Subjects who, through completion of the study, would have donated in excess of

               -  500 ml of blood in 14 days, or

               -  500 - 800 m l of blood in 14 days (unless approved by the Principal Investigator)

               -  1000 ml of blood in 90 days

               -  1250 ml of blood in 120 days

               -  1500 ml of blood in 180 days

               -  2000 ml of blood in 270 days

               -  2500 ml of blood in 1 year

          3. Participation in another clinical trial within the preceding 28 days of study start.

          4. Subjects who have:

               -  Systolic blood pressure less than 90 mm of Hg and more than 150 mm of Hg

               -  Diastolic blood pressure less than 60 m of Hg and more than 95 mm of Hg. Minor
                  deviations (1-3 mm Hg) at check-in may be acceptable at the discretion of the
                  physician/investigator

               -  Pulse rate below 50/min. and above 105/min.

          5. Female volunteers demonstrating a positive pregnancy screen or currently
             breast-feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vijayanthi G, MBBS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lotus Labs Pvt. Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lotus Labs Pvt. Ltd.</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2010</study_first_submitted>
  <study_first_submitted_qc>May 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2010</study_first_posted>
  <last_update_submitted>June 11, 2010</last_update_submitted>
  <last_update_submitted_qc>June 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>M.S. Mohan</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Crossover</keyword>
  <keyword>Ibuprofen and Pseudoephedrine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Pseudoephedrine</mesh_term>
    <mesh_term>Ephedrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

